Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →BPC-157 (Body Protection Compound-157) is an experimental synthetic peptide with no FDA-approved human use, so its side-effect profile is not well established. The most commonly reported effects — drawn from animal studies and patient self-reports — include injection-site irritation, nausea, fatigue, dizziness, and headaches. Long-term safety, cancer risk, and interaction data remain unknown, and the FDA has flagged safety concerns about its use in compounded products [1].
What is BPC-157?
BPC-157 stands for Body Protection Compound-157. It's a synthetic pentadecapeptide — a short chain of 15 amino acids — originally identified from a protein found in human stomach juice. Researchers designed it in the lab to study how the body protects and repairs its own tissues [2].
Where it comes from and how it's used
In animal studies, BPC-157 has been investigated for wound healing, tendon and ligament repair, gut-lining protection, and recovery from certain injuries [2][3]. It's often grouped with other research peptides like TB-500 (thymosin beta-4), which people sometimes stack with it — though again, this is investigational and not approved.
Outside of formal research, BPC-157 is sold and used in two main ways: as a subcutaneous or intramuscular injection prepared by a compounding pharmacy, and as an oral capsule or sublingual formulation. Both are considered off-label or investigational use, since no version has been approved for any specific human condition.
Is BPC-157 approved or regulated?
No. BPC-157 has not received FDA approval for any human condition. It is not a dietary supplement, and it is not a recognized prescription drug with an FDA label.
FDA status and the 503A/503B compounding picture
In 2023, the FDA reviewed BPC-157 for use in compounded medications and placed it on its Category 2 bulk substance list — a category for substances the agency believes raise significant safety risks. The FDA cited concerns including limited safety data, unclear purity standards, and possible immunogenicity (the body forming an immune reaction to it) [1].
This means licensed 503A compounding pharmacies — the small, state-regulated pharmacies that prepare customized prescriptions — generally cannot use BPC-157 to make compounded products under the FDA's current stance. Products sold online as "research chemicals" or "not for human use" sit entirely outside this regulatory system, with no enforced quality, purity, or sterility standards.
What side effects have been reported with BPC-157?
Because there are no large human clinical trials, the side-effect picture comes from three places: animal toxicology studies, small case series, and patient self-reports from forums and clinics. Below is what's most commonly described.
Commonly reported effects (injection-site, GI, fatigue)
| Side effect | How it's typically described | Route most associated |
|---|---|---|
| Injection-site reactions | Redness, mild swelling, bruising, or stinging at the spot of the shot | Subcutaneous / intramuscular |
| Nausea or stomach upset | Mild queasiness, usually short-lived | Oral and injection |
| Fatigue or sleepiness | Feeling unusually tired in the first days of use | Both |
| Headache | Mild, dull headache after dosing | Both |
| Dizziness or lightheadedness | Brief episodes, usually shortly after a dose | Both |
| Flushing or warmth | Temporary skin flushing | Injection |
These reports are mostly mild and self-limited, but they are not the result of controlled trials, so true frequency is unknown.
Less common or anecdotal reports
- Changes in appetite (up or down)
- Sleep disturbances or vivid dreams
- Heart palpitations or chest tightness
- Mood changes, including anxiety or low mood
- Allergic-type reactions (rash, itching) — possible signs of immunogenicity
- Worsening of pre-existing conditions
Are there serious or long-term risks?
This is the most important — and most uncertain — part of the BPC-157 conversation. Without long human trials, several theoretical risks remain open questions.
Cancer and tumor-growth concerns
A common question is whether BPC-157 causes cancer. The honest answer is: we don't know. BPC-157 appears to promote angiogenesis — the growth of new blood vessels — in animal studies [2][3]. Angiogenesis is part of normal healing, but it's also a process tumors use to grow. No published study has shown BPC-157 causing cancer in humans, and no study has shown it's safe in people with cancer either. Anyone with a personal or family history of cancer should treat this as a serious unknown and discuss it with their oncologist.
Cardiovascular and hormonal questions
Some animal research suggests BPC-157 may influence blood pressure regulation and the nitric oxide system [3]. What that means for humans with heart disease, high blood pressure, or on cardiac medications has not been studied. Effects on hormones such as growth hormone, cortisol, or thyroid have also not been systematically evaluated in people.
Unknowns from the lack of human trials
- Long-term safety beyond a few weeks of use
- Drug-drug interactions with prescription medications
- Safety in pregnancy, breastfeeding, or children (assume not safe — avoid)
- Effects in people with autoimmune conditions
- Purity, sterility, and dose accuracy of non-pharmacy-sourced products
Do side effects differ by route — oral vs injection?
Yes, somewhat. Injected BPC-157 is more associated with injection-site reactions — bruising, redness, tenderness — and, if non-sterile, with infection risk. Oral or sublingual BPC-157 is more associated with mild GI symptoms like nausea. Bioavailability also differs: injectable forms reach the bloodstream more directly, while oral peptides face stomach acid and may be partially broken down before absorption [2]. Side-effect severity hasn't been compared head-to-head in humans.
Who should avoid BPC-157?
Because safety data is limited, several groups should avoid BPC-157 entirely or only consider it under close medical supervision:
- Anyone who is pregnant, trying to conceive, or breastfeeding
- Children and adolescents
- People with active cancer or a history of cancer
- People with a strong personal or family history of certain cancers
- People with active or unstable cardiovascular disease
- People on blood thinners or with bleeding disorders
- People with autoimmune diseases
- Anyone with a known peptide allergy or prior reaction
What does the animal and clinical evidence say?
Most published BPC-157 research is in rodents. These studies suggest potential benefits in healing tendons, muscle, gut tissue, and certain nerve injuries, with relatively low acute toxicity at the doses tested [2][3]. However, animal data doesn't reliably predict human safety or effectiveness, and the small handful of human reports in the literature are not large, randomized, placebo-controlled trials.
In short: the preclinical picture is interesting, but it is not the same as proven human safety. Treat any benefit claim with that gap in mind.
How to reduce risk if you're considering BPC-157
If, after talking with a clinician, you and your provider decide to explore peptide therapy, the way you obtain the product matters as much as the molecule itself. The biggest avoidable risks with BPC-157 are not really about the peptide — they're about contaminated, mislabeled, or unsterile products from unregulated sellers.
Why a clinician-reviewed, pharmacy-sourced path matters
- A licensed clinician can review your full medical history, medications, and risk factors before recommending anything.
- A licensed compounding pharmacy follows sterility, purity, and labeling standards — "research chemical" sellers do not.
- A real prescription pathway gives you a clinician to call if you have a side effect, instead of an anonymous website.
- It's the only way to get clear documentation of what's actually in the vial.
Telehealth providers like Chia offer one such path: a clinician-reviewed evaluation, and — where clinically appropriate and legally permitted — a prescription filled by a licensed pharmacy. It's one of several legitimate options; the important thing is that the pathway involves a real clinician and a real pharmacy, not a gray-market vendor.
3-min quiz
Thinking about peptide therapy?
Talk to a licensed clinician about whether peptide therapy fits your goals, health history, and risk tolerance — and what legitimate, pharmacy-sourced options look like.
When to stop and seek medical care
Stop BPC-157 and contact a healthcare provider promptly if you experience any of the following:
- Signs of an allergic reaction: hives, swelling of the face/lips/tongue, trouble breathing
- Signs of infection at an injection site: increasing redness, warmth, pus, fever
- Chest pain, palpitations, shortness of breath, or fainting
- A new lump, growth, or worsening of a known mass
- Severe or persistent headaches, vision changes, or neurological symptoms
- Severe GI symptoms (persistent vomiting, blood in stool, severe abdominal pain)
Frequently asked questions
There isn't enough human data to call BPC-157 broadly safe. Short-term, mild side effects like injection-site irritation, nausea, fatigue, and headache have been reported, but long-term safety, cancer risk, and drug interactions are unknown. The FDA has flagged safety concerns and placed it on its Category 2 bulk substance list [1].
There is no published evidence that BPC-157 causes cancer in humans, but there is also no evidence proving it's safe in people with or at risk of cancer. Because it promotes blood-vessel growth in animal studies, the theoretical concern about tumor growth has not been ruled out [2][3]. Anyone with a cancer history should discuss this with their oncologist.
BPC-157 is not FDA-approved for any human use. In 2023, the FDA placed it on its Category 2 bulk substance list for compounding, citing safety concerns [1]. Licensed 503A compounding pharmacies generally cannot use it under the FDA's current stance.
Injected BPC-157 is more associated with injection-site reactions and, if non-sterile, infection risk. Oral or sublingual forms more often cause mild GI symptoms like nausea. Severity hasn't been compared head-to-head in human trials.
Some users combine BPC-157 with TB-500 (thymosin beta-4), another investigational peptide. There is no human safety data on this combination, and side effects and interactions are unknown. This is not something to attempt without clinician oversight.
AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health (DoctorMCP). The medication still requires review by a licensed clinician, and any recommendation depends on the patient's medical history and applicable law.
3-min quiz
Considering peptide therapy?
Chia's licensed clinicians can review your health history and discuss whether peptide therapy is appropriate, and what evidence-based, pharmacy-sourced options exist.
References
- 1.U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act — Category 2 (Substances Identified with Significant Safety Risks). FDA, updated 2023.
- 2.Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 2011;17(16):1612-1632.
- 3.Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and standard angiogenic growth factors: gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Current Pharmaceutical Design, 2018;24(18):1972-1989.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
